RIYADH, Saudi Arabia, Jan. 26, 2026 /PRNewswire/ — SKSHU Paint Co., Ltd., a leading provider of building coating solutions, showcased its latest range of high-performance, climate-adaptive products at Big 5 Construct Saudi, the Middle East’s premier construction industry event. The display reflected a broader industry shift toward integrated, sustainable technologies that enhance durability, energy efficiency, and indoor environmental quality.

As construction across the Gulf accelerates, developers face growing pressure to meet higher environmental and performance standards. In response, 3Trees’s exhibition introduced three core solutions to address these challenges: weather-resistant stone-effect coatings, odorless interior wall paints, and radiative cooling coatings designed to reduce surface heat loads. The lineup was developed to support developers in achieving greater long-term building resilience and occupant well-being under high-heat, high-UV conditions.

Visitors explored hands-on demo zones that turned technical features into real-world experiences. Thermal imaging demonstrated how radiative cooling coatings kept surfaces cooler than conventional options under the same lighting, pointing to their energy-saving potential and HVAC benefits.

3Trees also highlighted its local customization capabilities, showcasing stone-textured finishes and color treatments shaped by regional design trends. These lightweight materials suit large and high-rise projects, offering efficiency gains that matter for developers balancing performance and cost.

As indoor air quality becomes a growing priority, 3Trees’s odorless wall paint drew strong interest for its low-emission, low-odor formula. Designed for quick project turnaround and move-in readiness, it offers a cleaner, more comfortable option for high-end homes, hotels, and commercial spaces.

Beyond individual products, the company focused on its full-system approach, providing support from product selection and color design to technical guidance and on-site application. Each display sample was tailored to local trends, reflecting 3Trees’s attention to climate, aesthetics, and compliance in every detail.

The Middle East construction sector is moving toward materials that blend design, strength, and sustainability. 3Trees’s presence at Big 5 showcased solutions that support a more sustainable, efficient, and comfortable built environment through ongoing innovation and local collaboration.

About SKSHU Paint Co., Ltd.
Established in 2002, 3Trees is a global coatings provider dedicated to high-performance, environmentally responsible solutions for the building industry. Its portfolio covers exterior and interior paints, insulation, waterproofing, and decorative systems, supported by customized, locally adapted services that help clients build with confidence and meet evolving sustainability needs.

Contact:
Mr. Liang, GM of Overseas BU
WhatsApp: +86 18201750616
Ms. Ma, MKT Manager
+86 17866526571

SINGAPORE, Jan. 26, 2026 /PRNewswire/ — Leading Traditional Chinese Medicine (TCM) healthcare group Gu Sheng Tang TCM and Nanyang Technological University, Singapore (NTU Singapore) officially launched the Gu Sheng Tang Traditional Chinese Medicine Education and Research Programme today. As part of the programme, Gu Sheng Tang TCM has donated S$1.06 million to NTU, aimed at advancing TCM talent development and evidence-based research in Singapore, while supporting the country’s broader healthcare ecosystem.

The launch was formalised at a signing ceremony at PARKROYAL COLLECTION Pickering, with Mr Tan Kiat How, Senior Minister of State, Ministry of Digital Development and Information and Ministry of Health, as Guest of Honour.

The collaboration between Gu Sheng Tang TCM and NTU marks a key milestone in Gu Sheng Tang’s efforts to build an international expansion framework that integrates academia, technology and capital, in partnership with NTU. Through a structured long-term investment, Gu Sheng Tang TCM seeks to strengthen the expertise of TCM professionals in Singapore and reinforce the scientific, evidence-based foundations of TCM, thereby enhancing its standing and credibility within the healthcare system of Singapore.

“This partnership represents our long-term investment in the future of Traditional Chinese Medicine in Singapore,” expressed Mr Tu Zhiliang, Founder, Chairman and Chief Executive Officer of Gu Sheng Tang TCM. “By working closely with NTU, we aim to establish a stronger foundation for TCM through rigorous research and high-quality talent development, enabling TCM to play a more meaningful role within modern healthcare systems.”

“NTU’s partnership with Gu Sheng Tang TCM significantly strengthens the ecosystem for Chinese Medicine education and research in Singapore,” said Associate Professor Linda Zhong, Director, NTU Chinese Medicine Clinic. “Through deeper collaboration, visiting experts and enhanced clinical exposure, we can further raise the quality of training for our students and advance more rigorous, evidence-based TCM practice that will benefit patients and the wider community.”

Strengthening the Academic and Clinical Foundations of TCM

The partnership signifies a deep integration between a leading academic institution and a high-quality healthcare service provider. As Singapore faces a rapidly ageing population and rising healthcare needs, there is a growing interest in preventive and complementary medicine. As a result, the role of TCM has become increasingly significant.

NTU brings its strengths in education, clinical training and research to support the development of evidence-based Traditional Chinese Medicine practice in Singapore.

Gu Sheng Tang TCM’s strategic partnership with NTU is firmly centred on two core pillars, supported by NTU’s academic and research expertise, that will shape the future development of TCM: talent development and scientific research.

On the talent development front, the collaboration focuses on developing an internationally oriented TCM practitioner workforce. As part of the programme, Gu Sheng Tang TCM will regularly invite leading TCM experts from China to Singapore to conduct lectures and provide clinical mentorship as visiting professors. This will enable the direct transfer of advanced diagnostic techniques and extensive clinical experience to local practitioners, raising the overall standards of TCM care. In addition, there will be initiatives such as doctorate scholarships and support for overseas academic exchange programmes to help establish a joint international talent development framework for TCM.

On the research front, the partnership aims to strengthen the foundations of evidence-based TCM. By fostering closer integration between NTU’s strong research capabilities and Gu Sheng Tang TCM’s expanding clinical network, the collaboration will support rigorous research of international standards. This creates opportunities for applied research in real-world clinical settings, data-driven studies and practitioner development, further enhancing the scientific credibility of TCM.

Gu Sheng Tang established its operations in Singapore in 2024 and has embarked on rapid expansion since. As of December 2025, the group operates 16 clinics nationwide, with plans to expand to 50 clinics by the end of 2026.

This significant investment in education and research underscores Gu Sheng Tang’s strategic positioning of Singapore as a core market for long-term regional development, an innovation hub, and a benchmark for international expansion. It also reflects the broader trend within the TCM sector towards greater standardisation and alignment with internationally recognised research norms.

Supporting Singapore’s Healthcare Ecosystem

The Gu Sheng Tang–NTU programme aligns with Singapore’s broader healthcare priorities, particularly in areas such as healthy ageing, chronic disease management and preventive care. Traditional Chinese Medicine continues to play a complementary role in supporting patient wellbeing, and stronger research frameworks are increasingly important in building public trust and clinical credibility.

Through this collaboration, NTU researchers gain access to clinical insights and real-world practice environments, while Gu Sheng Tang practitioners benefit from exposure to academic research methodologies and structured learning pathways.

In 2025, three TCM formulations developed by Gu Sheng Tang TCM received approval from the Health Sciences Authority (HSA) of Singapore. Building on research inputs from this collaboration, the programme is expected to support the future registration of additional clinically validated, quality-controlled TCM products in Singapore, benefiting the wider population.

As an active proponent of the internationalisation of TCM, Gu Sheng Tang’s partnership with NTU not only enhances the sector’s standing in Singapore, but also contributes to public health outcomes and serves as a bridge for deeper China–Singapore collaboration in TCM. The partnership aims to support TCM’s role as a globally recognised complementary medical discipline and contribute meaningfully to the continued development of Singapore’s healthcare ecosystem.

For press assets, please download the press kit here.

About Gu Sheng Tang Traditional Chinese Medicine

Founded in 2010 and listed on the Hong Kong Stock Exchange in 2021 (Stock Code: 02273.HK), Gu Sheng Tang TCM is dedicated to providing high-quality traditional Chinese medicine services. The group operates over 100 medical institutions across China and Singapore, supported by more than 40,000 TCM physicians and having served more than 20 million patients. It is guided by its mission to empower traditional Chinese medicine with technology. Through digital healthcare platforms, A.I.-assisted diagnostic systems and an integrated online-to offline service model, the group continues to enhance healthcare accessibility and service quality, delivering scientific, credible and sustainable TCM healthcare solutions globally.

About Nanyang Technological University, Singapore

A research-intensive public university, Nanyang Technological University, Singapore (NTU Singapore) has 35,000 undergraduate and postgraduate students in the Business, Computing & Data Science, Engineering, Humanities, Arts, & Social Sciences, Medicine, Science, and Graduate colleges. 

NTU is also home to world-renowned autonomous institutes – the National Institute of Education, S Rajaratnam School of International Studies and Singapore Centre for Environmental Life Sciences Engineering – and various leading research centres such as the Earth Observatory of Singapore, Nanyang Environment & Water Research Institute and Energy Research Institute @ NTU (ERI@N).

Under the NTU Smart Campus vision, the University harnesses the power of digital technology and tech-enabled solutions to support better learning and living experiences, the discovery of new knowledge, and the sustainability of resources.

Ranked amongst the world’s top universities, the University’s main campus is also frequently listed among the world’s most beautiful. Known for its sustainability, NTU has achieved 100% Green Mark Platinum certification for all its eligible building projects. Apart from its main campus, NTU also has a medical campus in Novena, Singapore’s healthcare district.

For more information, visit www.ntu.edu.sg

JAKARTA, Indonesia, Jan. 26, 2026 /PRNewswire/ — Geely Auto launched the Geely EX2 in Indonesia and confirmed the start of local production, marking a key milestone in its localization strategy. Driven by a rapidly growing demand for smart, sustainable urban mobility, the launch of the Geely EX2 marks Geely Auto’s shift from initial product introduction to deep market localization, integrating global technology standards with local manufacturing capabilities.

Indonesia is one of Geely Auto’s strategically significant overseas markets, serving both as a key right-hand-drive market and a gateway to Southeast Asia. As the third model in Geely Auto’s local production line-up – following the Geely Starray EM-i and Geely EX5 – the Geely EX2 underscores Geely Auto’s dedication to strengthening the local electric vehicle ecosystem and its long-term commitment to Southeast Asia.

Designed for urban families and young professionals, the Geely EX2 delivers a “Smart Space Urban Car” experience, blending expressive design, intelligent technology, and a responsive, enjoyable driving experience. Comprehensive chassis adjustments tailored to Indonesia’s roads and driving habits ensure comfort on uneven streets and optimal stability in urban conditions. The blind spot detection system is specifically engineered for heavy motorcycle traffic, while the 540° transparent chassis view—unique in its class – empowers drivers to navigate complex urban roads with confidence.

As part of its localization strategy, Geely Auto has officially commenced local assembly of the Geely EX2 in Indonesia, with 46.5% local content, reinforcing its commitment to contributing to a sustainable and competitive automotive ecosystem in the country. Working closely with local partners, the program facilitates technology transfer, workforce development, and the growth of the domestic supply chain, while ensuring that locally produced vehicles continue to meet Geely Auto’s global quality and safety standards. Assembly quality is ensured via the Geely Manufacturing Enterprise System (GMES), maintaining consistency at every stage of production.

The Geely EX2 has continuously reshaped vehicle momentum across global markets. In 2025, it topped China’s car sales across all categories, with 460,000 units sold that year and 530,000 sold since its debut. In Brazil, the model became the second best-selling EV within 16 days of its launch. Following its success in Thailand, the launch of the Geely EX2 in Indonesia further expands its presence in Southeast Asia. It advances Geely’s ambition to sell the model in more than 100 countries worldwide.

SHANGHAI, Jan. 26, 2026 /PRNewswire/ — WuXi Biologics (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, jointly announced today the signing of a strategic collaboration agreement on the development and manufacturing of multiple next-generation bi-/multi-functional fusion programs from HanchorBio’s pipeline.

Under the agreement, WuXi Biologics will provide integrated, end-to-end biologics development and manufacturing services, including cell line development, process and bioassay development, drug product formulation development, and GMP manufacturing. The collaboration is designed to enhance CMC execution efficiency, accelerate clinical translation, and support scalable global development and manufacturing of HanchorBio’s innovative fusion protein portfolio derived from its Fc-Based Designer Biologics (FBDB™) platform.

This partnership reflects HanchorBio’s strategy to advance its platform-derived, multi-asset pipelines with development speed, manufacturing robustness, and capital efficiency from early clinical stages through commercialization. By leveraging WuXi Biologics’ proven capabilities in complex biologics and its global quality systems, HanchorBio aims to shorten development timelines and maintain flexibility across multiple clinical programs.

WuXi Biologics brings extensive experience in complex modalities, including bispecific and multi-specific antibodies, antibody-drug conjugates (ADCs), and fusion proteins. As of 2025, there are 945 projects on WuXi Biologics’ integrated platform, with approximately 60% are bi- and multi-specific antibodies, ADCs and fusion proteins, underscoring its track record in enabling accelerated development and manufacturing of advanced therapeutic modalities. Its proprietary technology platforms, such as WuXia™ TrueSite – targeted integration (TI)-based CHO cell line platform, and WuXiHigh^TM – high-throughput formulation development platform, are designed to enhance speed, quality, and scalability.

For HanchorBio, the collaboration supports continued expansion of its proprietary FBDB™ technology platform, which enables the rational design of multi-functional fusion proteins intended to modulate both innate and adaptive immunity. The partnership represents a significant step in aligning discovery innovation with industrial-scale and globally compliant execution as HanchorBio advances its oncology and autoimmune pipelines toward global clinical development.

Dr. Chris Chen, Chief Executive Officer of WuXi Biologics, said: ” We are excited to embark on this collaboration with HanchorBio, which underscores the strong trust they placed in WuXi Biologics’ comprehensive, end-to-end capabilities for developing next-generation biologics, especially complex molecules. By leveraging our industry-leading technology platforms, proven expertise, and unwavering commitment to quality, we strive to accelerate the development of HanchorBio’s innovative bi-/multi-fusion proteins and help bring transformative therapies to patients worldwide.”

Dr. Scott Liu, Founder, Chairman, and Chief Executive Officer of HanchorBio, commented: “This partnership with WuXi Biologics strengthens our ability to translate platform-driven innovation into high-quality clinical and commercial assets. As we advance multiple next-generation fusion protein programs, execution speed, manufacturing reliability, and scalability are critical. WuXi Biologics’ proven expertise in complex biologics and global development makes them a strong strategic partner as we build a differentiated, multi-asset immunotherapy pipeline.”

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany, Singapore and Qatar, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2025, WuXi Biologics is supporting 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing.

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com. 

Contacts
Media
PR@wuxibiologics.com
Business
info@wuxibiologics.com

About HanchorBio

Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (TPEx: 7827) is a global clinical-stage biotechnology company focused on immuno-oncology and immune-mediated diseases. The company is led by an experienced team with a proven track record in biologics discovery and global development, aiming to reshape the landscape of cancer therapies. HanchorBio’s proprietary Fc-based designer biologics (FBDB™) platform enables the design of multi-functional biologics with diverse targeting modalities, aiming to activate both innate and adaptive immune pathways to overcome the current challenges of anti-PD1/L1 immunotherapies. The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models. HanchorBio is advancing a portfolio of innovative biologics designed to address significant unmet medical needs through differentiated molecular configurations in R&D and scalable CMC strategies. For more information, please visit: https://www.HanchorBio.com 

Contacts
IRPR@hanchorbio.com 

Top ranking comes alongside recent acknowledgements from S&P Global, CDP and EcoVadis, reflecting Beko’s commitment to sustainability, innovation and advanced manufacturing

ISTANBUL, Jan. 26, 2026 /PRNewswire/ — Beko, a global leader in home appliances, has been recognised in the 2026 Corporate Knights Global 100, ranking 45th among the world’s most sustainable publicly listed companies and first globally in the household durables industry. Following a category leading ranking in the 2025 Corporate Knights Global 100, where Beko placed 68th overall, the company advanced 23 positions in 2026 while maintaining its #1 position in the household durables industry. This achievement reflects Beko’s continued progress in developing sustainability as a core driver of its strategy, operations and sustained growth.

Hakan Bulgurlu, Beko CEO

The Corporate Knights recognition builds on a series of recent global sustainability assessments that consistently position Beko among industry leaders. In 2025, Beko was named one of TIME Magazine’s World’s Most Sustainable Companies for the second-year running, earning a place in the Top 20 and securing the #1 position in its industry. Furthermore, the company achieved the highest score in the S&P Global Corporate Sustainability Assessment (CSA) within the DHP Household Durables Industry for the seventh consecutive year, was awarded a Gold Medal in the EcoVadis Sustainability Assessment, placing it in the top 3% of all companies assessed. In 2026, Beko once again achieved “Double A” status from the Carbon Disclosure Project (CDP) for both Climate Change and Water Security, placing the company among the global leaders in corporate transparency.

Turning Commitment into Action

These achievements recognise the importance Beko places on sustainability and real climate action. In 2024, the company invested 165 million Euros in environmental-related investments and expenditures. Today, low-carbon products generate for more than 70% of total revenue, while energy-efficient appliances continue to make up a significant portion of this share. Material efficiency initiatives embedded in product design delivered savings of more than 17,000 tonnes. Circularity is further strengthened through the use of over 27,800 tonnes of recycled plastics across manufacturing in 2024. In parallel, Beko scaled up its refurbishment activities, extending the life of more than 114,000 appliances in 2024 through its global refurbishment network.

“Our recognition in the Corporate Knights Global 100, alongside our leadership rankings from S&P Global, CDP, and EcoVadis, confirms that sustainability sits at the core of how we design, invest, and grow our business across the markets we operate. Together, these outcomes validate our commitment and prove that scale and innovation, when guided by responsibility, can deliver measurable impact for society, the economy, and our planet.” said Hakan Bulgurlu, CEO of Beko.

The Corporate Knights Global 100 is widely regarded as one of the most rigorous global sustainability rankings. The index assesses how effectively public-listed companies are developing sustainable economic models, focusing on sustainable revenue, investment, and growth, with ESG performance serving as a minimum threshold. Beko’s performance highlights its ability to scale sustainability across products, manufacturing and capital allocation, while delivering resilient business outcomes.

About Beko

Beko is an international home appliance company with a strong global presence, operating through subsidiaries in more than 55 countries with a workforce of over 50,000 employees and production facilities spanning multiple regions—including Europe, Asia, Africa, and the Middle East. Beko has 22 brands owned or used with a limited license (Arçelik, Beko, Whirlpool*, Grundig, Hotpoint, Arctic, Ariston*, Leisure, Indesit, Blomberg, Defy, Dawlance, Hitachi*, Voltas Beko, Singer*, ElektraBregenz, Flavel, Bauknecht, Privileg, Altus, Ignis, Polar). Beko became the largest white goods company in Europe with its market share (based on volumes) and reached a consolidated turnover of 10.6 billion Euros in 2024. Beko’s 28 R&D and Design Centers & Offices across the globe are home to over 2,300 researchers and hold more than 4,500 international registered patent applications to date. The company has achieved the highest score in the S&P Global Corporate Sustainability Assessment (CSA) in the DHP Household Durables industry for the seventh consecutive year (based on the results dated 16 October 2025).** The company has been recognized as the 17^th most sustainable company on TIME Magazine and Statista’s 2025 list of the World’s Most Sustainable Companies. Beko’s vision is ‘Respecting the World, Respected Worldwide.’ 

www.bekocorporate.com  

*Licensee limited to certain jurisdictions.  
**The data presented belongs to Arçelik A.Ş., a parent company of Beko.  

Beko Logo Corporate

NEW COMPANY WILL BE A LEADING MANUFACTURER OF SURFACE PROTECTION SOLUTIONS

COMPAGNIE CHARGEURS INVEST SA TO RETAIN 25% OWNERSHIP INTEREST

NEW YORK, Jan. 26, 2026 /PRNewswire/ — KPS Capital Partners, LP (“KPS”) announced today that, through a newly formed affiliate, it has entered into a definitive agreement under which KPS will acquire a controlling stake in Chargeurs Films de Protection SAS (“Novacel” or the “Company”). The selling shareholder, Compagnie Chargeurs Invest SA (“Chargeurs”) (ENXTPA:CRI) will invest alongside KPS and retain a 25% ownership interest in the Company. Financial terms of the transaction were not disclosed. Completion of the transaction is expected in the second quarter of 2026 and is subject to customary closing conditions and approvals.

Novacel is a leading global manufacturer of surface protection solutions across building exterior, building interior & equipment, industrial, appliances and transportation end-markets. The Company offers a full suite of solutions, including process and protection films, tapes, papers and specialty machines. Novacel is headquartered in Deville, France, has approximately 700 employees and operates six manufacturing facilities and three R&D centers across France, Italy and the United States.

Pierre de Villeméjane, Partner and Co-Head of KPS Mid-Cap Investments, said, “We are excited to acquire a controlling stake in Novacel, a differentiated surface protection solutions manufacturer with a diverse product portfolio, broad geographic footprint, best-in-class R&D capabilities and an attractive customer base. The Company’s solutions are essential to its customers’ manufacturing processes across a wide range of applications. We look forward to working with Novacel’s talented management team to build upon this great platform. Novacel’s strong brand, renowned R&D capabilities and commitment to quality, combined with KPS’ strategic, operational and financial resources, provide an ideal foundation for future growth.”

Philippe Denoix, Chief Executive Officer of Novacel, said, “KPS, with its demonstrated track record of manufacturing excellence is the ideal next owner of Novacel as it enters this next phase of growth as an independent company. We look forward to working closely together with KPS and our talented team to expand our technical leadership and continue delivering new, innovative high-quality products that provide significant value for our customers. KPS’ commitment to manufacturing excellence, operational improvement and innovation will enable us to build on Novacel’s strong market position and deepen our partnerships with customers globally.”

Michaël Fribourg, Chairman and Chief Executive Officer of Chargeurs, said, “We have been compelled by KPS’ strategic vision for Novacel and its proven track record in managing global manufacturing and industrial businesses. Chargeurs’ investment alongside KPS highlights our belief in the Company’s earnings growth and value creation potential under KPS’ direction, and we look forward to partnering with KPS in driving Novacel’s next phase of growth, with a focus on M&A build up in the surface protection market.”

Paul, Weiss, Rifkind, Wharton & Garrison LLP served as legal counsel and Rothschild & Co served as financial advisor to KPS.

About Novacel
Novacel is a leading global manufacturer of surface protection solutions across building exterior, building interior & equipment, industrial, appliances and transportation end-markets. The Company offers a full suite of solutions, including process and protection films, tapes, papers and specialty machines. Novacel is headquartered in Deville, France, has approximately 700 employees and operates six manufacturing facilities and three R&D centers across France, Italy and the United States. For more information about Novacel, visit www.novacel-solutions.com.

About Compagnie Chargeurs Invest
Compagnie Chargeurs Invest (ENXTPA:CRI) is a mixed industrial and financial company with a role as an operator and developer of global champions in industry and services, and as an investor with a culture of active portfolio management of high value-added businesses. Active in nearly 100 countries with around 2,600 employees, Compagnie Chargeurs Invest relies on the long-term commitment of Groupe Familial Fribourg, a committed controlling shareholder, and on its portfolio of assets, to meet the major challenges of its markets. Compagnie Chargeurs Invest achieved revenues of €729.6 million in 2024. For more information about Chargeurs, visit www.chargeurs.com.

About KPS Capital Partners
KPS, through its affiliated management entities, is the manager of the KPS Special Situations Funds, a family of investment funds with $19.5 billion of assets under management (as of September 30, 2025). For over three decades, the Partners of KPS have worked exclusively to realize significant capital appreciation by making controlling equity investments in manufacturing and industrial companies across a diverse array of industries, including basic materials, branded consumer, healthcare and luxury products, automotive parts, capital equipment and general manufacturing. KPS creates value for its investors by working constructively with talented management teams to make businesses better, and generates investment returns by structurally improving the strategic position, competitiveness and profitability of its portfolio companies, rather than primarily relying on financial leverage. The KPS Funds’ portfolio companies have aggregate annual revenues of approximately $21.2 billion, operate 202 manufacturing facilities in 21 countries, and have approximately 55,000 employees, directly and through joint ventures worldwide (as of September 30, 2025). The KPS investment strategy and portfolio companies are described in detail at www.kpsfund.com.

KPS Mid-Cap focuses on investments in the lower end of the middle market. KPS Mid-Cap targets the same type of investment opportunities and utilizes the same investment strategy that KPS’ flagship funds have for over three decades. KPS Mid-Cap leverages and benefits from KPS’ global platform, reputation, track record, infrastructure, best practices, knowledge and experience. The KPS Mid-Cap investment team is managed by Partners Pierre de Villeméjane and Ryan Harrison, who lead a team of experienced and talented professionals.

SINGAPORE, Jan. 26, 2026 /PRNewswire/ — UROVO Technology, a world-leading provider of industry application solutions, proudly announced the launch of the DT630 Enterprise-grade Smartphone Terminal at NRF 2026. Designed to address the dynamic needs of Logistics, Retail, and Healthcare, the DT630 redefines the AIDC landscape by elegantly combining the sleek, intuitive design of a premium consumer smartphone with the rugged reliability, powerful data capture, and long-term enterprise support  for mission-critical operations, seamlessly doubling as an intuitive device for everyday employee communication.

The New Standard for Enterprise Smartphone

As consumer and industrial device expectations converge, enterprises demand tools that frontline employees enjoy using, feature professional scanning engines for superior data capture, and meet IT’s rigorous requirements for rugged durability.

Slim Design, Rugged Core

Weighing only 240g and measuring just 10.4mm thin, the DT630 merges industrial-strength durability with an ultra-slim, ergonomic form. It features a 6.58-inch FHD+ display for clear, data-rich interaction. Built to endure demanding shifts, it carries an IP68 rating for dust and water resistance and survives 1.5-meter drops onto concrete—dramatically reducing maintenance costs.

Engineered for Effortless Data Capture

The DT630 introduces a human-centric scanning architecture designed to minimize operator fatigue and maximize productivity：

• Professional Rear Scan Engine: An innovative rear-positioned scanner with intuitive line-of-sight scanning enables faster, more natural operation — minimizing fatigue and maximizing productivity.

Always-Connected Performance

With support for 5G and Wi-Fi 6E, the DT630 delivers seamless, low-latency connectivity—ensuring real-time data flow throughout logistics and delivery operations.

Superior Performance

Powered by a 4nm octa core processor (AnTuTu 950K+) with a dedicated NPU, DT630 is ready for next-generation Edge AI applications. Runs Android 15, upgradeable to Android 19. 

50MP Camera • AI Image Enhancement Algorithm

Capture true-to-life images and 4K video even in low light.

AI-powered enhancement turns every shot into actionable insight.

The DT630 is a versatile, enterprise-grade mobile terminal designed for seamless frontline workflows across retail and logistics. Combining professional data capture with a familiar smartphone experience, it doubles as an employee’s daily work phone.

About Urovo

Founded in 2002, UROVO is the world’s leading industry application enabler, specializing in AI, Mobility, Barcode and RFID Technologies, Printers, and Payment Terminals. Committed to technological advancement and innovation, we provide cutting-edge digital solutions that drive smart transformation for clients across industries such as logistics, retail, finance, healthcare, manufacturing, government, and transportation.

Email: urovo@urovo.com